Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Immunovia’s Q1 presentation

LUND (SWEDEN) – Immunovia will publish its first quarter 2022 results on April 28, 2022 at 8:00 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 13:00 pm CET. The report together with the presentation slides will be available at www.immunovia.com   Philipp Mathieu, Acting CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and

Report from the Annual General Meeting of Rejlers AB (publ) on 21 April 2022

At the annual general meeting (the “AGM”) of Rejlers AB (publ), reg. no 556349-8426, (the “Company”), on 21 April 2022 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.rejlers.com.Adoption of the balance sheet and income statement, disposition regarding the Company’s results and discharge from liabilityThe AGM adopted the Company’s balance sheet and income

Nordic Mining starts early construction work at Engebø

Nordic Mining has, after closing of the acquisition of the main properties at Engebø, started early construction works. The early works includes preparing the properties for construction, continuation of detailed project planning and process for procurement of critical process equipment, and commencement of groundworks on process plant area and preparatory works for tunnelling. The early works is expected to last up to the completion of the remaining project financing, which is targeted in H1 2022, and secures important project developments that enables optimizations of the construction

Wallenstam initiates collaboration regarding Foreign-born Entrepreneur of the Year award

Wallenstam has initiated collaboration with the Internationella Företagare i Sverige Foundation, IFS, which awards the Foreign-born Entrepreneur of the Year prize annually. Since 1996, IFS has supported entrepreneurs and business owners with a foreign background in starting, running and developing companies. The foundation also strives to secure favorable conditions for enterprise and initiates activities to create networks among business owners with a foreign background and companies and organisations in Sweden.The Foreign-born Entrepreneur of the Year award – one of Sweden’s most

Presentation of 1[st] quarter 2022 results

Atea ASA will present its 1[st] quarter 2022 financial results on Thursday, 28 April 2022 at 08:00 CEST. The presentation will be held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo, Norway. In addition to presenting the 1[st] quarter 2022 results, the company will provide an update on the business. The quarterly report, presentation material, and webcast will be available at:https://www.atea.com/investors/financial-reports/ For further information, please contact:Robert Giori, CFO, Atea ASA, mobile (+47) 934 09 188  About AteaAtea is the leading supplier of IT

Solving water loss with smart digital solutions - You can’t manage what you can’t measure

The fifth episode in the “Solving Water Loss for Life” webcast series, presented by GF Piping Systems, can now be streamed on demand.Which smart, digital solutions can utilities implement on the road to solving water loss? What does the water supply of the future look like? These are two important questions faced by the entire water sector. After having focused on a broad range of topics, from the causes of water loss all the way to cutting-edge technical solutions, episode five of the “Solving Water Loss for Life” webcast series set its sights on smart innovative technologies that are

Press invitation to Vattenfall’s Annual General Meeting 2022

The Annual General Meeting (AGM) of Vattenfall AB will take place on Thursday 28 April at CEST 09.30 at Vattenfall’s head office, Evenemangsgatan 13 in Solna. The AGM will also be broadcasted live on the web at group.vattenfall.com/seAnyone wishing to attend must register in advance via Vattenfall's Press Office at press@vattenfall.com On the day of AGM the registration will open at CET 08.00 and the doors will close at CET 09.00. The confirmation of the attendance and a relevant ID is required, as well as a valid Covid-certificate, showing that you have received vaccine against Covid-19.

Wärtsilä launches Smart Realities: virtual and augmented simulation solutions for scalable and realistic training experience

Wärtsilä Corporation, Trade press release, 21 April 2022 at 11:00 AM EEST· Next-level immersive learning environment, using the latest Augmented Reality (AR) and Virtual Reality (VR) technology. · Focused and effective extended reality learning applications that increase accessibility, learning velocity, trainee throughput for a significantly lower cost. · Allowing commercial training providers to increase training profit and align the costs with the incoming training revenues through an OPEX based business model. · Utilising existing simulator content through unified software,

AAK’s Annual Report for 2021 has been published

AAK’s Annual Report for 2021 has been published and is available in English and Swedish at the AAK website, www.aak.com, and at the company’s headquarters.  For more information, please contact:Gabriella GrotteHead of IR and Corporate CommunicationsMobile: +46 737 16 80 01E-mail: gabriella.grotte@aak.comThis is information that AAK AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10:00 a.m. CET on April 21, 2022. About AAKEverything AAK does is about Making Better Happen™. We specialize in plant-based

Heimstaden Bostad Funds and Acquires PLATFORM_’s Residential Project in Edinburgh

Heimstaden Bostad AB has agreed to fund and acquire PLATFORM_’s 464-home residential project in Edinburgh for SEK 1.5 billion (£124.4 million). A build contract was placed simultaneously and practical completion is scheduled for mid-2024.The development is in the Bonnington regeneration area, 2 km (1.2 miles) north of Edinburgh’s city centre, to which it will be connected by tram from 2023. A quarter of the predominantly two- and three- bedroom homes will be offered as intermediate housing at discounts of around 40% to open market rents. The property will have a total of 30,200 sqm (325,000

Oncopeptides publishes the 2021 Annual Report

STOCKHOLM — April 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the 2021 Annual Report has been published.The Annual Report summarizes an extraordinary eventful year, including significant regulatory hurdles. The year started with a major milestone, the accelerated approval of Pepaxto® (INN melphalan flufenamide) in the US. This was followed by an application to the European Medicines Agency, EMA, for marketing authorization in Europe, and the

Invitation to MTG’s financial results for the first quarter of 2022

STOCKHOLM — Modern Times Group MTG AB (“MTG”) (publ) will publish its financial results for the first quarter of 2022 at 14.00 CET on Wednesday 27 April 2022.MTG will host a conference call at 15.00 CET on the same day, hosted by MTG’s President and CEO Maria Redin and CFO Lasse Pilgaard. To participate, please dial in using details below: Sweden, Stockholm +46 (0) 856 618 467United Kingdom +44 (0) 844 481 9752United States, New York +1 646 741 3167Std International Dial-In: +44 (0) 2071 928 338 Confirmation code: 248 319 2 Participation is also

Interim report January-Mars 2022

Summary first quarter · Net sales increased by 19.6% to KSEK 25 296 (21 142). · Gross profit increased by 6.9% to KSEK 17 224 (16 112). · Operating income before depreciation (EBITDA) was KSEK 5 735 (7 374). · Operating income (EBIT) was KSEK 4 211 (5 915). · The operating margin was 16.6 (22.1) % · Net profit was KSEK 3 288 (4 665). · Cash flow from operating activities amounted to KSEK 8 395 (15 837). · Earnings per share amounted to SEK 0.41 (0.58)A few words from our CEO - Q1 2022 We continued to experience strong demand for our products during the first

Eficode Has Earned the DevOps with GitHub on Microsoft Azure Advanced Specialization

Helsinki, Finland, April 21, 2022 - Eficode  has earned the DevOps with GitHub on Microsoft Azure advanced specialization, a validation of a services partner’s deep knowledge, extensive experience and proven success in implementing secure software development practices applying DevOps principles and using Azure and GitHub solutions. Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their DevOps technical practices, are able to earn the DevOps with GitHub on Microsoft Azure advanced

Read original

CS MEDICA A/S: CS MEDICA has been approved by Hong Kong Custom and has received a trial order for the Hong Kong market

CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has been approved by the Hong Kong customs and is now able to sell its CANNASEN® CBD products in Hong Kong.  The Company has just received its first trial order from its sponsor/importer in Hong Kong.CS MEDICA has just received the final approval from Hong Kong customs, the Drug Registration Office, confirming that the CANNASEN® CBD product line can be sold to Hong Kong.  With reference to the less than 1PPB THC certificates showing zero traces of THC, the CANNASEN® CBD product line can be sold in Hong Kong without

Q-Free: SaaS contract in the USA - 28 MNOK

Q-Free has received an additional agreement for one of its key statewide ATMS contracts in the USA. The agreement adds scope to provide cloud infrastructure hosting and respective cloud support for Q-Free's OpenTMS solution for an initial period from April 2022 until June 2023 and has a total value of approximately 28 MNOK. The agreement could be prolonged for several years. - We are very pleased to see that Q-Free has continued to expand its ATMS cloud deployments and that the customer has decided to expand the scope of services Q-Free provides. The agreement gives us a nice and steady

BioStock: Immunicum participates in new cancer research consortium

In an effort to bring new cancer treatments faster to patients, the Dutch National Growth Fund will support a new cancer research consortium called Oncode-PACT with 325 MEUR. Cancer therapy biotech Immunicum has announced being part of the consortium, contributing with its expertise in dendritic cell biology to design novel cancer immunotherapies.Read the article at biostock.se: https://www.biostock.se/en/2022/04/immunicum-participates-in-new-cancer-research-consortium/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)

· First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this disease · First patient enrolled in US pilot phase leading up to the US pivotal phase of the study with expected start in H2 2022 · DTx aims to form a part of a differentiated offering in rare lung disease Gothenburg, April 21, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot phase of COMPANION[1], a clinical study of a digital cognitive behavioral therapy for

Presentation of Probi’s Q1 report 2022

Probi’s report for the first quarter 2022 will be published on Tuesday, 26 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://tv.streamfabriken.com/probi-q1-2022 The presentation can also be followed via a telephone conference on the following telephone number: Sweden: +46 8 50 55 83 55UK: +44 33 33

Finnair removes the face mask requirement on flights where it is not an authority requirement

Many countries are removing Covid-19-related restrictions due to the increasing vaccination coverage and the mild form of the recent virus variants. In line with this, Finnair is now lifting the requirement to wear a face mask on board all flights.   As of 25 April, customers and crew are no longer required to wear a face mask onboard Finnair flights, unless it is specifically required by the authorities of the destination or origin country.   Those who wish to continue to wear a mask when traveling are naturally welcome to do so. “The aircraft is regarded as a low-risk environment

BioStock: CombiGene strives for a broader pipeline

In 2021, Swedish gene therapy company CombiGene signed an exclusive, global license agreement for candidate CG01 with Spark Therapeutics, which entitles CombiGene to up to 328.5 million USD excluding royalties. The parties are now putting the finishing touches on the preclinical work, after which Spark will be responsible for and pay for the first clinical studies in patients with drug-resistant focal epilepsy.Read the full article about CombiGene at biostock.se: https://www.biostock.se/en/2022/04/combigene-strives-for-a-broader-pipeline/ This is a press release from BioStock -

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 99 - 21 APRIL 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 56/2022. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

SelectImmune Pharma releases new film about immunotherapy

Today we are proud to present a new film entitled “Immunotherapy - a complement to antibiotics’’. The film tells the story about SelectImmune Pharma’s drug development program and the scientific discoveries that have defined new and exciting tools for treating infections. SelectImmune is developing several drug candidates with exciting potential. In the film you will meet the multinational and talented research team and hear their stories about their favourite molecules and technologies. You will also meet Dr. Björn Wullt, who has used innate immunotherapy to treat patients with bladder

New Nordic Schools releases Kwizie to help teachers instantly create engaging and inspiring quizzes with AI

Kwizie instantly creates and grades quizzes from any text-based resource, giving insights into each student’s level of understanding and saving teachers endless hours.Finnish education company  New Nordic Schools  launches  Kwizie  – an online tool that helps teachers engage with their students and save endless hours by instantly creating and grading quizzes with cutting-edge Artificial Intelligence (AI).  

There are no items matching the current filter
There are no more items matching the current filter
Back to top